IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro

Journal of Immunotherapy

Volumn 30, Issue 6, 2007, Pages 624-633

  Egan, James E ^a   Quadrini, Karen J ^a   Santiago Schwarz, Frances ^b   Hadden, John W ^a   Brandwein, Harvey J ^a   Signorelli, Kathy L ^a  

^a IRX Therapeutics Inc   (United States)

^b FARMINGDALE STATE COLLEGE   (United States)

Author keywords

Cancer; Cytokines; Dendritic cells; Head and neck squamous cell carcinoma; Immunotherapy; IRX 2

Indexed keywords

CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; IRX 2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOCYTOSIS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; CELL DIFFERENTIATION; CELL SHAPE; CYTOKINES; DENDRITIC CELLS; ENDOCYTOSIS; HUMANS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 34547769186     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3180691593     Document Type: Article

References (56)

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
2. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
3. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104:2235-2246.
4. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952.
5. Dubsky P, Ueno H, Piqueras B, et al. Human dendritic cell subsets for vaccination. J Clin Immunol. 2005;25:551-572.
6. Santiago-Schwarz F. Dendritic cells: friend or foe in autoimmunity? Rheum Dis Clin North Am. 2004;30:115-134.
7. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
8. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996;93:2588-2592.
9. Cella M, Engering A, Pinet V, et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature. 1997;388:782-787.
10. Lechmann M, Berchtold S, Hauber J, et al. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 2002;23:273-275.
11. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998;28:2760-2769.
12. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 2002;100:1362-1372.
13. Scandella E, Men Y, Gillessen S, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 2002;100:1354-1361.
14. Randolph GJ. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol. 2001;13:267-274.
15. Sozzani S, Allavena P, D'Amico G, et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol. 1998;161:1083-1086.
16. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
17. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100.
18. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-251.
19. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
20. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279-1288.
21. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
22. Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3:483-490.
23. Chaux P, Moutet M, Faivre J, et al. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest. 1996;74:975-983.
24. Hoffmann TK, Muller-Berghaus J, Ferris RL, et al. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res. 2002;8:1787-1793.
25. Thurnher M, Radmayr C, Ramoner R, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer. 1996;68:1-7.
26. Whiteside TL, Stanson J, Shurin MR, et al. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol. 2004;173:1526-1534.
27. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678-689.
28. Hadden J, Verastegui E, Barrera JL, et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol. 2003;3:1073-1081.
29. Middel P, Hemmerlein B, Fayyazi A, et al. Sinus histiocytosis with massive lymphadenopathy: evidence for its relationship to macrophages and for a cytokine-related disorder. Histopathology. 1999;35:525-533.
30. Meneses A, Verastegui E, Barrera JL, et al. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int Immunopharmacol. 2003;3:1083-1091.
31. Chomarat P, Dantin C, Bennett L, et al. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol. 2003;171:2262-2269.
32. Lee AW, Truong T, Bickham K, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20(suppl 4):A8-A22.
33. Reddy A, Sapp M, Feldman M, et al. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood. 1997;90:3640-3646.
34. Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 2000;60:2209-2217.
35. Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182:389-400.
36. Hadden JW, Saha A, Sosa M, et al. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice. Int J Immunopharmacol. 1995;17:821-828.
37. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-146.
38. Lechmann M, Krooshoop DJ, Dudziak D, et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med. 2001;194:1813-1821.
39. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev. 2000;177:134-140.
40. Spisek R, Bretaudeau L, Barbieux I, et al. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2001;50:417-427.
41. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97:3466-3469.
42. Jongmans W, Tiemessen DM, van Vlodrop IJ, et al. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother. 2005;28:480-487.
43. Rogers PR, Croft M. CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J Immunol. 2000;164:2955-2963.
44. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
45. Bender A, Sapp M, Schuler G, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121-135.
46. Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003;26:374-383.
47. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 2002;99:351-358.
48. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
49. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumorspecific T lymphocytes. Cancer Res. 2003;63:3688-3694.
50. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999;162:3231-3236.
51. Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res. 2002;8:3369-3376.
52. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21:873-886.
53. Romero P, Pittet M, Dutoit V, et al. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine. 2002;20(suppl 4):A2-A7.
54. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol. 2003;170:2817-2823.
55. Lou Y, Wang G, Lizee G, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004;64:6783-6790.
56. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.